Clinical trials: Pneumococcal Immunization
- Condition Pneumococcal Immunization
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Healthy Volunteers
Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine
The objective of this clinical trial is to evaluate the consistency of the 15-valent pneumococcal conjugate vaccine in three batches of the 3-month-old population, as well as the immunogenicity and safety of vaccination in the…
- Trial name
- NCT05939219
- Testing
- 15-valent pneumococcal conjugate vaccine 202210001, 15-valent pneumococcal conjugate vaccineY202210002, 15-valent pneumococcal conjugate vaccineY202210003
- Where
- China
- Volunteers
- 2,346 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Infections, Meningococcal
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered…
- Trial name
- NCT00758264
- Testing
- Meningococcal vaccine GSK134612, Pneumococcal vaccine GSK1024850A
- Where
- 5 sites in Mexico, Taiwan
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12…
- Trial name
- NCT06838000
- Testing
- PCV21, 20vPCV
- Where
- 38 sites in United States, Estonia and 2 more
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Streptococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
The purpose of this phase IIIb study is to determine whether children who have not received a 3-dose primary vaccination with the pneumococcal conjugate vaccine before their 6 months of age, can receive the vaccine as part of a…
- Trial name
- NCT00345358
- Testing
- Synflorix, Infanrix IPV/Hib
- Where
- 10 sites in Finland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination…
- Trial name
- NCT01153893
- Testing
- Pneumococcal vaccine GSK1024850A, InfanrixTM
- Where
- Nigeria
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
- Trial name
- NCT00581035
- Testing
- Prevenar and Meningitec, Prevenar, Meningitec
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Prevention of Meningococcal Infection
Persistence of Antibody Response to N. Meningitidis Group C in Children
Persistence of Antibody Response to N. meningitidis Group C in Children
- Trial name
- NCT00316654
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Poland, Spain
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pneumococcal Disease
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.
- Trial name
- NCT06622109
- Testing
- 20-valent Pneumococcal Conjugate Vaccine
- Where
- Japan
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00474539
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 27 sites in Spain
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Streptococcal
Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
The purpose of this observer blind study is to assess the safety in terms of fever >39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK…
- Trial name
- NCT00547248
- Testing
- Synflorix, Tritanrix-HepB, Hiberix
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine manufactured with Polysorbate 80 compared to a 13-valent pneumococcal conjugate (13vPnC)…
- Trial name
- NCT00366548
- Testing
- 13 valent pneumococcal conjugate vaccine with Polysorbate 80, 13 valent pneumococcal conjugate vaccine without Polysorbate 80
- Where
- 14 sites in Poland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Bacterial
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
- Trial name
- NCT07406347
- Testing
- Pn-MAPS30plus, PCV20
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children
This study will aim to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' 10-valent pneumococcal conjugate vaccine GSK1024850A when co-administered with Japanese DTPa vaccine as a 3-dose…
- Trial name
- NCT01027845
- Testing
- Pneumococcal vaccine GSK1024850A, DTPa
- Where
- 16 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule
The purpose of this study is to assess the safety and reactogenicity of 3 different dose levels of inactivated poliovirus vaccine based on Sabin strains (sIPV) in healthy participants, using conventional Salk IPV (cIPV) as an…
- Trial name
- NCT03566940
- Testing
- sIPV, cIPV
- Where
- 3 sites in Philippines
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Pneumococcal Infections
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
Primary Objective: To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution Secondary Objective: To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic…
- Trial name
- NCT00488371
- Testing
- Pneumococcal Conjugated Vaccine (Prevnar®)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Immunization
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06824181
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 27 sites in United States, Chile and 2 more
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Streptococcal
Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™
The purposes of this study are: To demonstrate the immunogenicity in terms of antibody response following primary vaccination of Korean infants with the pneumococcal conjugate vaccine GSK 1024850A compared to Prevenar™ when…
- Trial name
- NCT00680914
- Testing
- Pneumococcal vaccine GSK1024850A (Synflorix), Prevenar, GSK Biologicals' Hiberix™
- Where
- 14 sites in South Korea
- Volunteers
- 503 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal…
- Trial name
- NCT00452452
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 9 sites in Poland
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer